CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ampio Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ampio Pharmaceuticals Inc
9800 Mount Pyramid Court, Suite 400
Phone: (720) 437-6500p:720 437-6500 ENGLEWOOD, CO  80112  United States Ticker: AMPEAMPE
This company ceased filing statements with the SEC on 4/15/2024.
Business Summary
Ampio Pharmaceuticals, Inc. is a drug discovery and development company. The Company is focused on combining scientific, clinical, and manufacturing capabilities to develop therapies aimed at treating conditions for which limited treatment options exist.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
6500 Real estate
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board J. KevinBuchi 68 5/28/2022 10/13/2021
Chief Executive Officer, Director Michael A.Martino 68 5/28/2022 10/13/2021
Chief Financial Officer, Secretary Daniel G.Stokely 60 1/1/2020 7/31/2019
Independent Director Elizabeth V.Jobes 57 2/8/2022 2/8/2022
Independent Director David R.Stevens 74 6/8/2011 6/8/2011

Business Names
Business Name
AMPE
DMI Acquisition Corp.
DMI Bio Sciences, Inc.
DMI Life Sciences, Inc.
Luoxis Diagnostics

General Information
Number of Employees: 6 (As of 2/1/2024)
Outstanding Shares: 1,135,358 (As of 3/15/2024)
Shareholders: 96
Stock Exchange: OTC
Federal Tax Id: 260179592
Fax Number: (720) 437-6501
Email Address: info@ampiopharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, October 29, 2024